Aronne, Director of the Comprehensive Weight Control Center at Weill Cornell Medicine in New York City
specialized compounded options were used historically for flexible dosing until regulatory restrictions changed in 2025
GLP-1 Reduces appetite, slows gastric emptying GIP Enhances insulin, improves fat metabolism Glucagon Increases energy expenditure, burns fat Based on Phase 2 clinical trial data (published in NEJM, 2023), retatrutide's side effects are primarily gastrointestinal, similar to other GLP-1 agonists but with some differences due to the glucagon component
Lyophilized peptide powder should be stored at -20C, protected from light and moisture, and kept sealed until use
This is the same active ingredient in the injectable version of Wegovy and became available for private prescription in June 2026
Biol Pharm Bull 39:163173